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Summary
 
DCs (dendritic cells) function as sentinels of the immune system. They traffic from the blood to
the tissues where, while immature, they capture antigens. They then leave the tissues and move
to the draining lymphoid organs where, converted into mature DC, they prime naive T cells.
This suggestive link between DC traffic pattern and functions led us to investigate the chemo-
kine responsiveness of DCs during their development and maturation. DCs were differentiated
either from CD34
 
1
 
 hematopoietic progenitor cells (HPCs) cultured with granulocyte/mac-
rophage colony–stimulating factor (GM-CSF) plus tumor necrosis factor (TNF)-
 
a
 
 or from
monocytes cultured with GM-CSF plus interleukin 4. Immature DCs derived from CD34
 
1
 
HPCs migrate most vigorously in response to macrophage inflammatory protein (MIP)-3
 
a
 
, but
also to MIP-1
 
a
 
 and RANTES (regulated on activation, normal T cell expressed and secreted).
Upon maturation, induced by either TNF-
 
a
 
, lipopolysaccharide, or CD40L, DCs lose their
response to these three chemokines when they acquire a sustained responsiveness to a single
other chemokine, MIP-3
 
b
 
. CC chemokine receptor (CCR)6 and CCR7 are the only known
receptors for MIP-3
 
a
 
 and MIP-3
 
b
 
, respectively. The observation that CCR6 mRNA expres-
sion decreases progressively as DCs mature, whereas CCR7 mRNA expression is sharply up-
regulated, provides a likely explanation for the changes in chemokine responsiveness. Similarly,
MIP-3
 
b
 
 responsiveness and CCR7 expression are induced upon maturation of monocyte-
derived DCs. Furthermore, the chemotactic response to MIP-3
 
b
 
 is also acquired by CD11c
 
1
 
DCs isolated from blood after spontaneous maturation. Finally, detection by in situ hybridiza-
tion of MIP-3
 
a
 
 mRNA only within inflamed epithelial crypts of tonsils, and of MIP-3
 
b
 
mRNA specifically in T cell–rich areas, suggests a role for MIP-3
 
a
 
/CCR6 in recruitment of
immature DCs at site of injury and for MIP-3
 
b
 
/CCR7 in accumulation of antigen-loaded ma-
ture DCs in T cell–rich areas.
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D
 
endritic cells (DCs)
 
1
 
 are professional APCs that are
found in all lymphoid and nonlymphoid organs (1).
DCs are bone marrow–derived and likely migrate as pre-
cursors through blood stream to tissues, where they be-
come resident cells such as Langerhans cells in the epider-
mis. Moreover, after pathogen invasion, DCs are probably
recruited at the site of inflammation (2), as illustrated in the
rat, where intratracheal antigen instillation induces accu-
mulation of DCs in the airway epithelium (3). In the pe-
riphery, DCs such as Langerhans cells capture the antigens
(4–8), then migrate via the lymphatics and home to the T
cell–rich area of lymph nodes, where they are called inter-
digitating cells (IDCs) (9–14). At this site, they present the
processed antigens to naive T cells and generate an antigen-
specific primary T cell response (15–18). During their mi-
gration from peripheral tissues to lymphoid organs, DCs
 
1
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undergo a maturation process encompassing dramatic
changes in phenotype and functions (11, 19, 20). In partic-
ular, immature DCs such as fresh Langerhans cells capture
and process soluble proteins efficiently and are effective at
activating specific memory and effector T cells. Con-
versely, mature DCs such as IDCs of lymphoid organs are
poor in antigen capture and processing but markedly effi-
cient in naive T cell priming (4–7, 21, 22). This last differ-
ence correlates with the levels of expression of MHC class II
and accessory molecules such as B7, which are much
higher on mature than on immature DCs (23–27).
Although signals regulating the complex traffic pattern of
DCs are not fully understood, chemokines are probably
involved. Chemokines are small molecular mass proteins
(8–10 kD) that regulate leukocyte migration and activation
(28–31). They are secreted by activated leukocytes themselves
and by stromal cells, including endothelial cells and epithelial
cells upon inflammatory stimuli (28–31). Responses to
chemokines are mediated by seven transmembrane–spanning
G protein–coupled receptors (30, 32, 33). Several chemokines
such as monocyte chemotactic protein (MCP)-3, MCP-4,
macrophage inflammatory protein (MIP)-1
 
a
 
, MIP-1
 
b
 
,
RANTES (regulated on activation, normal T cell expressed
and secreted), stromal cell–derived factor (SDF)-1, thymus-
expressed chemokine (Teck), and macrophage-derived chemo-
kine have been reported to attract DCs in vitro (34–38).
Moreover, signals provided by TNF-
 
a
 
 and LPS are known
to induce in vivo migration of resident DCs from the
tissues to the draining lymphoid organs (20, 37–40).
However, the relationship between signals inducing DC
migration in vivo and their responses to chemokines is not
known.
In this study, we have taken advantage of the well-estab-
lished control of CD34
 
1
 
 hematopoietic progenitor cell
(HPC; 41–43) and monocyte (22, 44) cultures to study the
chemokine responsiveness of DCs during their differentia-
tion and maturation. Focusing on CC chemokine receptor
(CCR)6 (45–48) and CCR7 (49) and their known ligands
(47, 50–52), we found that chemokine receptor expression
and the subsequent chemokine responsiveness are indeed
integral parts of the maturation process of DCs. In addition,
in situ localization of chemokines active on immature ver-
sus mature DCs provides a likely explanation for at least
part of the DC traffic pattern.
 
Materials and Methods
 
Hematopoietic Factors, Reagents, and Cell Lines.
 
Recombinant hu-
man (rh)GM-CSF (specific activity: 2 
 
3
 
 10
 
6
 
 U/mg; Schering-
Plough Research Institute, Kenilworth, NJ) was used at a saturat-
ing concentration of 100 ng/ml. rhTNF-
 
a
 
 (specific activity: 2 
 
3
 
10
 
7 
 
U/mg; Genzyme, Boston, MA) was used at an optimal concen-
tration of 2.5 ng/ml (42). rhSCF (specific activity: 4 
 
3 
 
10
 
5
 
 U/mg,
R&D Systems, Abington, UK) was used at an optimal concentra-
tion of 25 ng/ml. rhIL-4 (specific activity: 2 
 
3
 
 10
 
7
 
 U/mg, Scher-
ing-Plough Research Institute) was used at a saturating concen-
tration of 50 U/ml. Recombinant human chemokines MIP-1
 
a
 
(specific activity: 2 
 
3 
 
10
 
5 
 
U/mg, 9 
 
3 
 
10
 
12
 
 U/M), RANTES
(specific activity: 10
 
4 
 
U/mg, 8 
 
3 
 
10
 
10
 
 U/M), MIP-3
 
a
 
 (specific
activity: 4 
 
3 
 
10
 
5 
 
U/mg, 3 
 
3 
 
10
 
12
 
 U/M) and MIP-3
 
b
 
 (specific
activity: 10
 
4 
 
U/mg, 9 
 
3 
 
10
 
10
 
 U/M) were obtained from R&D
Systems. LPS was used at 10 ng/ml (Sigma Chemical Co., St.
Louis, MO).
The murine CD40 ligand transfected cell line (CD40L L cells)
was produced in the laboratory and used as stimulator of DC
maturation (53).
 
Generation of DCs from Cord Blood CD34
 
1
 
 HPCs.
 
Umbilical
cord blood samples were obtained after full-term delivery. Cells
bearing CD34
 
1
 
 antigen were isolated from mononuclear frac-
tions through positive selection as previously described (42, 54),
using anti-CD34
 
1
 
 mAb (Immu-133.3, Immunotech, Marseille,
France), goat anti–mouse IgG-coated microbeads (Miltenyi Bio-
tec GmBH, Bergisch Gladbach, Germany), and Minimacs separa-
tion columns (Miltenyi Biotec GmBH). In all experiments the
isolated cells were 80–99% CD34
 
1
 
. After purification, CD34
 
1
 
cells were cryopreserved in 10% DMSO.
Cultures were established in the presence of stem cell factor,
GM-CSF, and TNF-
 
a
 
 as previously described (42) in endotoxin-
free medium consisting of RPMI 1640 (GIBCO BRL, Gaithers-
burg, MD) supplemented with 10% (vol/vol) heat-inactivated fe-
tal bovine serum (Life Technologies, Pontoise, France), 10 mM
Hepes, 2 mM 
 
l
 
-glutamine, 5 
 
3 
 
10
 
2
 
5 
 
M 
 
b
 
-mercaptoethanol, and
100 
 
m
 
g/ml gentamycin (Schering-Plough, Levalois, France) (re-
ferred to as complete medium). After thawing, CD34
 
1
 
 cells were
seeded for expansion in 25–75 cm
 
2
 
 culture vessels (Linbro; ICN
Biomedicals, Aurora, OH) at 2 
 
3 
 
10
 
4
 
 cells/ml. Optimal condi-
tions were maintained by splitting these cultures at days 5 and 10
with medium containing fresh GM-CSF and TNF-
 
a
 
 (cell con-
centration: 1–3 
 
3 
 
10
 
5
 
 cells/ml). At day 12, between 70 and 90%
of the cells were CD1a
 
1
 
 DCs.
 
Isolation of Immature and Mature DCs According to CD86 Expres-
sion by FACS
 
Ò
 
 Sorting.
 
After 12 d of culture in the presence of
GM-CSF and TNF-
 
a
 
, cells were collected and labeled with
FITC-conjugated OKT6 (CD1a; Ortho Diagnostic System, Rar-
itan, NJ) and PE-conjugated IT2.2 (CD86; PharMingen, San Diego,
CA). Cells were separated according to CD1a and CD86 expres-
sion into immature CD1a
 
1
 
CD86
 
2
 
 and mature CD1a
 
1
 
CD86
 
1
 
DC populations using a FACStarplus
 
Ò
 
 (laser setting: power 250
mW, excitation wavelength 488 nm; Becton Dickinson, Sunny-
vale, CA). All the procedures of staining and sorting were per-
formed in presence of 0.5 mM EDTA to avoid cell aggregation.
Reanalysis of the sorted populations showed a purity 
 
.
 
98%.
 
Generation of DCs from Peripheral Blood Monocytes.
 
Monocytes
were purified by immunomagnetic depletion (Dynabeads; Dynal,
Oslo, Norway) after preparation of PBMCs followed by a 52%
Percoll gradient. The depletion was performed with anti-CD3
(OKT3), anti-CD19 (4G2), anti-CD8 (OKT8), anti-CD56
(NKH1, Coulter Corp., Hialeah, FL), and anti-CD16 (ION16,
Immunotech) mAbs. Monocyte-derived dendritic cells were pro-
duced by culturing purified monocytes for 6–7 d in the presence
of GM-CSF and IL-4 (44).
 
Induction of Maturation of In Vitro–generated DCs.
 
CD34
 
1
 
 HPCs
were cultured until day 6 in presence of GM-CSF plus TNF-
 
a
 
and in presence of GM-CSF alone from days 6 to 12 in order to
preserve their immaturity. Immature DCs from CD34
 
1
 
 HPCs or
monocyte-derived DCs were activated for 3–72 h in the presence
of TNF-
 
a
 
 (2.5 ng/ml), LPS (10 ng/ml), or CD40L transfected L
cells (one L cell for five DCs) as described elsewhere (55).
 
Purification of CD11c
 
1
 
 DCs from Peripheral Blood or Tonsils.
 
CD11c
 
1
 
 DCs were prepared as previously described from pe-
ripheral blood or tonsils (56). In brief, tonsils obtained from chil-
dren undergoing tonsillectomy were finely minced and digested 
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with collagenase IV and DNase I (Sigma Chemical Co.). The
collected cells were centrifuged through Ficoll-Hypaque with
SRBCs (BioMérieux, Lyon, France) for 15 min at 500 rpm, then
for 30 min at 2,000 rpm. Mononuclear cells from peripheral
blood were isolated by Ficoll-Hypaque. CD3
 
1
 
 T cells (OKT3),
CD19
 
1
 
 B cells (4G7), and CD14
 
1
 
 monocytes (MOP9) were re-
moved from the resulting low density cells by magnetic beads
(anti–mouse Ig-coated Dynabeads [Dynal]). A second depletion
was performed with anti-NKH1, anti–glycophorine A (Immuno-
tech), and anti-CD20 (1F54). The remaining cells were stained
with the following mAbs: anti-CD1a FITC (OKT6); anti-CD14
FITC, anti-CD57 FITC, anti-CD16 FITC, anti-CD7 FITC,
anti-CD20 FITC, anti-CD3 FITC (Becton Dickinson); anti-
CD4 PE-Cy5 (Immunotech), and anti-CD11c PE (Becton Dick-
inson). CD4
 
1
 
CD11c
 
1
 
lineage
 
2
 
 DCs were isolated by cell sorting
using a FACStarPlus
 
Ò
 
 (laser setting: power 250 mW, excitation
wavelength 488 nm). All the procedures of depletion, staining,
and sorting were performed in presence of 0.5 mM EDTA. Re-
analysis of the sorted population showed a purity 
 
.
 
97%.
 
Chemotaxis Assay.
 
Cell migration was evaluated using a
chemotaxis microchamber technique (48-well Boyden micro-
chamber; Neuroprobe, Pleasanton, CA; reference 57). In brief,
MIP-3
 
a
 
 and MIP-3
 
b
 
, MIP-1
 
a
 
, and RANTES were diluted to
concentrations ranging from 1 to 1,000 ng/ml in RPMI 1640
medium, and were added to the lower wells of the chemotaxis
chamber. 10
 
5
 
 cells/well (or 5 
 
3 104 cells/well for CD11c1 DCs)
in 50 ml of RPMI 1640 medium were applied to the upper wells
of the chamber, with a standard 5-mm pore polyvinylpyrroli-
done-free polycarbonate filter (Neuroprobe) separating the lower
wells. The chamber was incubated at 378C in humidified air with
5% CO2 for 1 h. Then, cells that had migrated to the underside of
the filter were stained with Field’s A and Field’s B (BDH Chemi-
cals, Ltd., Abingdon, Essex, UK) and counted using an image an-
alyzer (software: Vision Explorer and ETC 3000; Graphtek, Mir-
mande, France) in two randomly selected low power fields
(magnification:  320). Each assay was performed in duplicate and
the results were expressed as the mean 6 SD of migrating cells
per two fields.
Extraction of Total RNA and Synthesis of cDNA. Cells were pre-
pared as described above, and total RNA was extracted by the
guanidinium thiocyanate method as mentioned by the manufac-
turer (RNAgents total RNA isolation system; Promega, Madi-
son, WI). After DNAse I treatment (RQ1 RNAse free DNAse;
Promega), RNA was quantified by spectrophotometry and qual-
ity was evaluated by electrophoresis in formaldehyde denaturing
conditions. First strand cDNA was synthetized from total RNA
extracted in RNAse-free conditions. The reaction was performed
with 5 mg of total RNA, 25 ng/ml oligo dT12-18 primers (Phar-
macia, Orsay, France) and the Superscript kit (SuperScript II
RNase H2 Reverse Transcriptase; GIBCO BRL), as described by
the manufacturer. For all samples, synthesis of cDNA was con-
trolled and calibrated by reverse transcriptase (RT)-PCR using
b-actin primers for 21 cycles.
RT-PCR Analysis. Semi-quantitative PCR was performed in
a Perkin Elmer 9,600 thermal cycler, in a final volume of 100 ml
reaction mixture containing 2.5 U AmpliTaq enzyme (5 U/ml,
Perkin Elmer, Paris, France) with its 13 buffer, 0.2 mM of each
dNTP (Perkin Elmer), 5% DMSO, and 1 mM of each forward
and reverse primer. CCR6 and CCR7 primers (sequence data
available from EMBL/GenBank/DDBJ under accession numbers
Z79784 and L08176, respectively) were designed within regions
of lowest homology between the chemokine receptors. 180/
CCR6 59-ATTTCAGCGATGTTTTCGACTC-39 forward
primer,  21081/CCR6 59-GGAGAAGCCTGAGGACTTGTA-
39 reverse primer, 1154/CCR7 59-GATTACATCGGAGA-
CAACACC-39 forward primer and 21202/CCR7 59-TAG-
TCCAGGCAGAAGAGTCG-39 reverse primer were used for
RT-PCR and sequencing. For both chemokine receptors, the
reaction mixture was subjected to 30 and 35 cycles of PCR with
the following conditions: 948C for 1 min, 61.58C for 2 min, and
728C for 3 min. PCR products were visualized on 1.2% agarose
gels containing 0.5 mg/ml ethidium bromide. Reaction products
migrating at the predicted size (1,021 bp for CCR6 and 1,067 bp
for CCR7) were gel purified and subcloned into pCRII TA
cloning vector (Invitrogen, Leek, The Netherlands) for sequenc-
ing verification on an ABI 373A Sequencer (Applied Biosystems,
Inc., Foster City, CA) using dye terminator technology. Two
Figure 1. Responses to MIP-3a and MIP-3b during development/
maturation of DCs from CD341 HPCs. CD341 HPCs were cultured in
presence of GM-CSF plus TNF-a for 13 d. (A) Migration assays were
performed between days 10 and 13. Results represent the means of opti-
mal responses for each chemokines obtained in 20 independent experi-
ments. (B) At the indicated time points, aliquots of cells were recovered
and tested for their response to MIP-3a (10–1,000 ng/ml) and to MIP-3b
(10–1,000 ng/ml), the optimal concentrations being shown. Results are
representative of more than three experiments. Migration assays were per-
formed in Boyden microchambers. Results are expressed as number of
migrating cells per two low power fields (original magnification: 320).376 Regulation of Dendritic Cell Migration during Maturation
other oligonucleotides, 2622/CCR6 59-GCTGCCTTGGGT-
GTTGTATTT-39 and 1662/CCR7 59-AGAGGAGCAGCA-
GTGAGCAA-39, were used as probes for hybridization with the
PCR products separated on 1.2% agarose gel and blotted onto
Hybond N1 membranes (Amersham, Les Ulis, France).
Calcium Fluorimetry. Intracellular Ca21 concentration was
measured using the fluorescent probe Indo-1, according to the
technique reported by Grynkiewicz et al. (58). In brief, cells were
washed in PBS and resuspended at 107 cells/ml in complete
RPMI 1640 medium (see above). Then, cells were incubated for
45 min at room temperature with 3 mg/ml Indo-1 AM (Molecu-
lar Probes, Inc., Eugene, OR) in the dark. After incubation, cells
were washed and resuspended in HBSS/1% FCS at 107 cells/ml.
Before measurement of intracellular Ca21 concentration, cells
were diluted 10-fold in HBSS/10 mM Hepes/1.6 mM CaCl2
preheated at 398C. Samples were excited at 330 nm with contin-
uous stirring and the Indo-1 fluorescence was measured as a func-
tion of time at 405 nm (dye is complexed with Ca21) and 485 nm
(Ca21-free medium) in a 810 Photomultiplier Detection System
(software: Felix; Photon Technology International, Monmouth
Junction, NJ). Results are expressed as the ratio of values ob-
tained at the two emission wavelengths.
In Situ Hybridization. In situ hybridization was performed as
previously described (59). Two-couple primers were used for
amplifying by RT-PCR the majority of the open reading frame
of MIP-3a and MIP-3b genes (sequence data available from
EMBL/GenBank/DDBJ under accession numbers D86955 and
U77180, respectively). 177/MIP-3a 5 9 -TTGCTCCTGGCT-
GCTTTG-39 forward primer and 2425/MIP-3a 59-ACCCTC-
CATGATGTGCAAG-39 reverse primer, 125/MIP-3b 59-CTG-
CTGGTTCTCTGGACTTC-39 forward primer and 2439/
MIP-3b 59-CACACTCACACTCACACACAC-39 reverse primer
were used as described above with an annealing temperature at
628C. Then, PCR products were cloned into pCRII TA cloning
vector (Invitrogen) for the generation of sense and antisense
probes with the adapted promoters. Sense and antisense 35S-labeled
probes of MIP-3a and MIP-3b were obtained by run off tran-
scription of the 367-bp and 435-bp fragments, respectively. 6-mm
human tonsil sections were fixed in acetone and 4% para-
formaldehyde followed by 0.1 M triethanolamine/0.25% acetic
anhydride. The sections were hybridized overnight, RNAse A
treated and exposed for 24 d. After development sections were
stained with hematoxylin.
Results
Differential Responsiveness to MIP-3a and MIP-3b during
Development of CD341-derived DCs. As a way to under-
stand the regulation of DC traffic, we have studied the re-
sponse to various chemokines of DCs at different stages of
maturation. DCs were generated from CD341 HPCs cul-
Figure 2. Dose responses to MIP-3a and to MIP-3b of CD341-derived DCs at different stages of development/maturation. CD341 HPCs were cul-
tured in presence of GM-CSF plus TNF-a for 13 d. Expression of CD1a (FITC) and CD86 (PE) is shown at days 6, 10 and 13 of culture (top). Dose re-
sponses to MIP-3a and to MIP-3b are shown at the same time points (bottom). Migration assays were performed in Boyden microchambers. Results are
expressed as number of migrating cells per two low power fields (original magnification: 320). Results are representative of more than three experiments.377 Dieu et al.
tured in the presence of GM-CSF plus TNF-a, and tested
at different days of culture for their ability to migrate in re-
sponse to chemokines in Boyden microchambers. MIP-3a
and MIP-3b recruited two to three times more CD341-
derived DCs than did MIP-1a or RANTES (Fig. 1 A,
mean of 20 experiments). However, MIP-3a and MIP-3b
attracted DCs collected at different time points of the cul-
ture (Fig. 1 B). The response to MIP-3a was already de-
tectable at day 4, maximal at days 5–6, and lasted until day
10. At days 13–14, the response to MIP-3a was usually
lost. In contrast, the response to MIP-3b, which could not
be detected before day 10, peaked at day 13, and persisted
beyond day 15 (data not shown). Of note, at early time
points (Fig. 2, Day 6), when most of the cells in culture
were still DC precursors (CD1a2CD862), the response to
MIP-3a could be detected at concentrations of 1–10 ng/ml
(depending on the experiment). In contrast, 4 d later, when
almost all cells were immature DCs (CD1a1CD862), $300
ng/ml were needed to attract the cells (Fig. 2, Day 10),
suggesting a progressive desensitization of the cells during
maturation. Relatively high concentrations of MIP-3b
(300 ng/ml) were also needed to recruit mature DCs
(CD1a1CD861) (Fig. 2, Day 13). Checkerboard analysis
established that MIP-3a and MIP-3b induced chemotaxis
and not chemokinesis of DCs (data not shown).
To confirm the relation between the stage of maturation
and the response to MIP-3a and MIP-3b, CD341-derived
DCs were FACSÒ sorted at day 10 of culture according to
CD86 expression into immature DCs (CD1a1CD862) and
mature DC (CD1a1CD861). CD1a1CD862 responded
exclusively to MIP-3a, whereas CD1a1CD861 responded
mainly to MIP-3b (Fig. 3). These observations also con-
firmed that the cells recruited by MIP-3a and MIP-3b
were indeed DCs (CD1a1). The correlation between DC
maturation and chemokine responsiveness was further illus-
trated when the immaturity of DCs was preserved by re-
moving TNF-a from days 6 to 12 and when their matura-
tion was synchronized by addition of TNF-a, LPS, or
CD40L. As shown in Fig. 4 A, response to MIP-3a had
strongly decreased after 48 h of maturation with TNF-a,
LPS, and CD40L. Meanwhile, the response to MIP-3b
was induced by all three signals, CD40L and LPS being
more potent than TNF-a. In kinetics experiments, the re-
sponse to MIP-3a decreased by 50–70% after only 24 h of
CD40 activation and was completely lost at 72 h. The re-
sponse to MIP-3b was already maximal after 24 h of CD40
activation (Fig. 4 B) and required relatively high concentra-
tion of chemokine (100–300 ng/ml) at 48 h (Fig. 4 C).
Taken together, these results establish that immature
CD341-derived DCs respond to MIP-3a, whereas mature
DCs respond to MIP-3b.
Responses to MIP-3a and MIP-3b Parallel the Expression of
Their Respective Receptors, CCR6 and CCR7, on CD341-derived
DCs. To define the mechanisms of regulation of MIP-3a
and MIP-3b responsiveness, the expression of their respec-
tive receptors, CCR6 (45–48) and CCR7 (49) mRNA,
was studied by semi-quantitative RT-PCR. During DC
development from CD341 HPCs, CCR6 mRNA was first
detected at day 6 and increased up to day 10, after which it
decreased and became barely detectable at day 14. In con-
trast, CCR7 mRNA appeared at day 10 and steadily increased
up to day 14 (Fig. 5 A). Moreover, CD40L-dependent
maturation induced progressive downregulation of CCR6
mRNA that became almost undetectable after 72 h, and
upregulation of CCR7 mRNA as early as 24 h after (Fig. 5
B). Similar results were obtained after either LPS- or TNF-
a–induced DC maturation (data not shown). The upregu-
lation of CCR7 mRNA after activation was confirmed by
Southern blot analysis of cDNA libraries (data not shown).
In line with the migration assays and the regulation of
CCR6 and CCR7 expression, MIP-3a induced a Ca21
flux exclusively in resting/immature DC (Fig. 6 A), and
MIP-3b induced the same in mature DCs only (indepen-
dently of the maturation signal, CD40 activation is shown
on Fig. 6 B). Maximal Ca21 fluxes were observed with 30
ng/ml of MIP-3a and 30 ng/ml of MIP-3b, on immature
and mature DCs, respectively (Fig. 6, C and D).
These results show that changes in responsiveness to
MIP-3a and MIP-3b are linked to the regulation of
CCR6 and CCR7 mRNA expression, and suggest that
CCR6 and CCR7 are the major functional receptors ex-
pressed on DCs for MIP-3a and MIP-3b, respectively.
The Response to MIP-3b Is Also Induced upon Maturation of
Monocyte-derived DCs. Monocyte-derived DCs, generated
by culturing monocytes in presence of GM-CSF1IL-4
for 6 d, are typically immature DCs (CD1a1, CD142,
CD80low, CD86low, and CD832) (22, 44). They migrated
in response to MIP-1a and RANTES but not to MIP-3a
(data not shown) or MIP-3b (Fig. 7). The lack of response
of monocyte-derived DCs to MIP-3a is in accordance
with the absence of CCR6 expression on those cells (45,
46). Upon maturation induced by TNF-a, LPS, or CD40L,
responses to MIP-1a and RANTES were lost, whereas re-
sponse to MIP-3b was induced (Fig. 7, A and B). As with
Figure 3. CD1a1CD862 immature DCs and CD1a1CD861 mature
DCs respond to MIP-3a and MIP-3b, respectively. CD341 HPCs were
cultured in the presence of GM-CSF plus TNF-a. At day 10, DCs were
FACSÒ sorted according to CD86 expression into CD1a1CD862 imma-
ture DCs and CD1a1CD861 mature DCs, and their response to MIP-3a
(10–1,000 ng/ml) and MIP-3b (10–1,000 ng/ml) were determined by
migration assays in Boyden microchambers. Results are expressed as index
of migrating cells (ratio chemokine/medium), the optimal concentrations
being shown. Results are representative of three experiments.378 Regulation of Dendritic Cell Migration during Maturation
CD341-derived DCs, the response to MIP-3b correlated
with the upregulation of CCR7 mRNA expression ob-
served upon maturation induced by TNF-a (Fig. 8 A),
LPS (data not shown), or CD40L (Fig. 8 B). Again, upreg-
ulation of CCR7 occurred at early time points (3 h) after
TNFR or CD40 signaling. Moreover, migration and
chemokine receptor expression data were in agreement
with Ca21 flux results (data not shown).
Those results extend to monocyte-derived DCs the con-
cept that upon maturation, DCs lose their responsiveness to
various chemokines while becoming sensitive to a single
chemokine, MIP-3b.
Peripheral Blood CD11c1 DCs Migrate in Response to
MIP-3b after Maturation. We next studied the chemotac-
tic activities of MIP-3a and MIP-3b on immature
CD11c1 DCs isolated from peripheral blood (or tonsils).
Freshly isolated DCs did not migrate in response to MIP-3a,
or to MIP-3b (Fig. 9 A), an observation that correlates
with the absence of CCR6 (data not shown) and CCR7
mRNA expression in these cells (Fig. 9 B). However, the
maturation that is known to occur after overnight culture
with GM-CSF (56) turned on the response of CD11c1 DC
to MIP-3b but not to MIP-3a. Once more, the response
to MIP-3b correlated with the induction of CCR7
mRNA expression (Fig. 9 B).
Therefore, although immature CD11c1 DCs freshly iso-
lated from blood cannot respond to MIP-3a, these results
show that maturation-dependent responsiveness to MIP-3b
also applies to ex vivo–isolated DCs.
In Vivo MIP-3a Is Expressed in Inflamed Epithelium and
MIP-3b within T Cell–rich Areas of Tonsils. The physiologi-
cal relevance of these findings was then addressed through
the analysis of MIP-3a and MIP-3b mRNA expressions by
in situ hybridization on sections of inflamed tonsils.
mRNA for MIP-3a was detected at high levels in inflamed
epithelial crypts but not in T cell–rich areas or in B cell fol-
licles (Fig. 10, A–C). In fact, MIP-3a expression was re-
stricted to cells lining the epithelial crypts (Fig. 10 D). In
contrast, expression of MIP-3b mRNA was restricted to T
cell–rich areas (Fig. 10, F–H). The strongest signal was
present in scattered cells, with a distribution overlapping
that of IDCs (Fig. 10, F–I). Outside the paracortical area,
no signal could be detected in B cell follicles or in epithelial
Figure 5. CCR6 mRNA downregulation and CCR7 mRNA upregu-
lation during CD341-derived DC activation/maturation induced by
TNF-a or CD40L. (A) CD341 HPCs were cultured in the presence of
GM-CSF plus TNF-a for 14 d. At the indicated time points, aliquots of
cells were recovered, mRNA was extracted, and expressions of CCR6
and CCR7 mRNA were determined. (B) CD341 HPCs were cultured in
the presence of GM-CSF plus TNF-a until day 6 and in the presence of
GM-CSF alone from day 6 to 12 to preserve their immaturity. At day 12,
DCs were cultured for 72 h in presence of GM-CSF and CD40L and the
expression of CCR6 and CCR7 mRNA were assessed at the indicated
time points. Expression of CCR6 and CCR7 mRNA were determined
by semi-quantitative RT-PCR (30, 35 cycles). The results at 35 cycles are
shown and PCR for b-actin are shown at 21 cycles as an internal mRNA
control. Results are representative of three experiments.
Figure 4. Different signals triggering DC maturation block the response
to MIP-3a and induce that to MIP-3b. CD341 HPCs were cultured in
presence of GM-CSF plus TNF-a until day 6 and in presence of GM-CSF
alone from day 6 to 12 to preserve their immaturity. (A) At day 12, DCs were
cultured for 48 h in presence of GM-CSF with or without TNF-a (2.5
ng/ml), LPS (10 ng/ml), or CD40L and assessed for their response to
MIP-3a (10–1,000 ng/ml) and to MIP-3b (10–1,000 ng/ml), the optimal
concentrations being shown. (B) At day 12, DCs were cultured for 72 h
in the presence of GM-CSF and CD40L and their response to MIP-3a
(10–1,000 ng/ml) and to MIP-3b (10–1,000 ng/ml) were assessed at the
indicated time points, the optimal concentrations being shown. (C) At
day 12, DCs were cultured for 48 h in presence of GM-CSF and CD40L.
Dose responses to MIP-3a and MIP-3b are shown. Migration assays were
performed in Boyden microchambers. Results are expressed as number of
migrating cells per two low power fields (original magnification: 320).
Results are representative of more than three experiments.379 Dieu et al.
crypts (Fig. 10, F–H). Fig. 10, A and F (serial sections),
shows clear absence of MIP-3b expression within epithelial
crypts where MIP-3a was abundantly present. Sense
probes for MIP-3a and MIP-3b did not generate back-
ground hybridization (Fig. 10, E and J).
Therefore, MIP-3a expression is restricted to inflamed
epithelium at the site of antigen entry, where immature
DCs should be recruited. In contrast, MIP-3b is only de-
tected in paracortical areas, where mature IDCs home and
generate primary T cell responses.
Discussion
Chemokine responsiveness appears to be one important
functional feature that characterizes the stage of DC matu-
ration. Immature DCs respond to MIP-3a, RANTES, and
MIP-1a. Upon maturation, DCs lose their responsiveness
to these chemokines to become sensitive to a single
chemokine, MIP-3b.
Taking advantage of culture conditions that tightly con-
trol DC maturation, we have found that immature DCs,
which very efficiently capture and process the antigens, mi-
grate in response to MIP-1a, RANTES, and MIP-3a, in
line with previous reports (34–36, 45). But in agreement
with recent observations (60), mature DCs that have lost
their aptitude to internalize antigens (21, 44, 61) cannot be
recruited by these chemokines anymore. However, along
with the ability to prime naive T cells, they have acquired
responsiveness to MIP-3b. Furthermore, microenviron-
mental signals, like TNF-a and LPS, or T cell signals, such
as CD40L, induce loss of response to MIP-3a, MIP-1a,
and RANTES and acquisition of response to MIP-3b.
These same signals induce DC maturation characterized by
a rapid loss of antigen uptake capacities (21, 44, 62, 63).
The link between DC maturation and migration pattern is
further supported by the observation that the same signals,
such as TNF-a and LPS that induce DC maturation in
vitro, also trigger migration in vivo (20, 37–40). Thus, the
modulation of chemokine responsiveness is part of a coordi-
nated regulation of functions that defines the stage of DC
maturation. Such a connection between maturation/activa-
tion and chemokine responsiveness is not unique to DCs.
In particular, resting and activated (64) or naive and mem-
ory (65, 66) T cells are not recruited by the same chemo-
kines. Also memory and naive B cells respond to stromal
cell–derived factor (SDF)-1, whereas germinal center B
cells do not (67). Altogether, these observations suggest
that the recruitment of immune cells in vivo would be de-
pendent on their stages of development and maturation/ac-
tivation.
The mechanism underlying the modulation of chemo-
kine responsiveness during activation/maturation of DC
includes the regulation of the chemokine receptor expres-
sion. Therefore, the change in expression levels of CCR6
and CCR7 contributes to the functional shifts characteriz-
ing DC maturation. Other molecules linked to function are
also regulated, particularly molecules involved in antigen
uptake (Fc receptors, mannose receptors, and other lectins)
or skin homing (E-cadherin), which are downregulated upon
maturation. In contrast, molecules involved in migration
Figure 6. MIP-3a and MIP-3b in-
duce Ca21 flux on only immature and
mature DCs, respectively. CD341
HPCs were cultured in the presence of
GM-CSF plus TNF-a until day 6 and in
the presence of GM-CSF alone from day
6 to 12 (immature/resting DCs). At day
12, DCs were cultured for 48 h in pres-
ence of GM-CSF and CD40L (mature/
activated DC). Immature/resting DC
(A) and mature/CD40-activated DCs
(B) were tested for their response to
MIP-3a (1,000 ng/ml) and to MIP-3b
(1,000 ng/ml) in Ca21 flux. Dose re-
sponses in Ca21 flux are shown for MIP-
3a and MIP-3b on, respectively, imma-
ture/resting DCs (C) and mature/
CD40-activated DCs (D). Results are
representative of three experiments.380 Regulation of Dendritic Cell Migration during Maturation
(matrix metalloproteases [our observations]), in antigen
presentation (MHC class II, protease/protease inhibitor,
DC-LAMP [de Saint Vis, B., manuscript in preparation), in
costimulation (CD80, CD86) (68) or in T cell commit-
ment (IL-10, IL-12) (69) are upregulated. CCR6 gene ex-
pression is progressively downregulated on CD341-derived
DCs after activation/maturation with TNF-a, LPS, or
CD40L. The downregulation of CCR6 mRNA expression
upon DC activation is in line with a previous study show-
ing downregulation of CCR1, CCR2, and CCR5 mRNA
on monocytes after TNF-a or LPS activation (70). Also,
on T cells, CD3 activation induces a rapid loss of CCR1
and CCR2 (64) and PHA activation induces downregula-
tion of CCR6 (47). However, in addition to the downreg-
ulation of CCR6 mRNA expression, which is not com-
pletely extinct on mature DCs, other mechanisms might be
involved in the loss of MIP-3a responsiveness (31). Signals
inducing maturation might directly interfere with CCR6
signalization or indirectly cause CCR6 desensitization
through engagement by endogenous MIP-3a, which is ef-
fectively produced by DCs upon CD40 activation (our ob-
servations).
In contrast to CCR6, CCR7 mRNA, absent on imma-
ture DCs, is induced upon maturation and the rapidity of
this induction (detected within 3 h) probably reflects a di-
rect effect of DC activation through CD40 or TNFR.
Similar activation-dependent upregulation of CCR7 had
been previously reported on T and B cells (71, 72). In this
context, CCR7 expression is also induced on B and T cells
after EBV infection (72) or herpesvirus infection (73), re-
spectively. Furthermore, the expression of other receptors
is activation-dependent. In particular, on T cells, expres-
sion of CCR1, CCR2A, and CCR2B is IL-2 dependent
(64), and CXCR4 expression is induced by PHA activation
(66). In addition, IL-2 increases the response of NK cells to
chemokines (74, 75).
Most of the known chemokines bind several receptors.
However, with regards to the correlation between the mi-
gration profiles, the expression of chemokine receptors,
and Ca21 flux responses, it is likely that CCR6 and CCR7
are the major functional receptors for MIP-3a and MIP-
Figure 7. The response to MIP-3b is induced upon maturation of monocyte-
derived DCs. DCs were generated by culturing monocytes in presence of GM-
CSF1IL-4 for 6 d. (A) DCs were cultured in the presence of GM-CSF (resting)
or in the presence of GM-CSF and CD40L (activated). Dose responses to MIP-
1a, RANTES, and MIP-3b were determined after 48 h. (B) DCs were cultured
for 48 h in the presence of GM-CSF with or without TNF-a (2.5 ng/ml), LPS
(10 ng/ml), or CD40L and assessed for their responses to MIP-1a (10–1,000 ng/
ml) and to MIP-3b (10–1000 ng/ml), the optimal concentrations being shown.
Migration assays were performed in Boyden microchambers. Results are ex-
pressed as number of migrating cells per two low power fields (original magnifi-
cation: 320). Results are representative of more than three experiments.
Figure 8. CCR7 is rapidly induced upon CD40 and TNF-a activation
of monocyte-derived DCs. DCs were generated by culturing monocytes
in presence of GM-CSF1IL-4 for 6 d. DCs were activated in presence of
GM-CSF plus TNF-a or GM-CSF1CD40L. At the indicated time
points, the expression of CCR7 mRNA was assessed by semi-quantitative
RT-PCR (30, 35 cycles). Results at 35 cycles are shown and PCR for
b-actin are shown at 21 cycles as an internal mRNA control. Results are
representative of three experiments.381 Dieu et al.
3b, respectively, expressed on DCs. MIP-3a response was
observed on immature CD341-derived DCs, but not on
monocyte-derived DCs, in line with absence of CCR6 ex-
pression (45, 46). The reason for this lack of CCR6 expres-
sion is under investigation and might reflect either that
monocyte-derived DCs represent a different DC subset, or
that IL-4 blocks CCR6 expression.
Although MIP-3a appears as the most potent chemo-
kine in inducing migration of immature CD341-derived
DCs, the DC population responding to MIP-3a in vivo
has not yet been identified. Immature CD11c1 blood DCs
are unresponsive, but Langerhans cells or their direct pre-
cursors (CD341CLA1; reference 76) represent potential
target populations. In this regard, precursor cells (days 4–6
of culture) are responsive to low concentrations of MIP-3a
(1–10 ng/ml) compared with their more differentiated but
still immature progenies (day 10 of culture). In contrast, the
response to MIP-3b appears to be a general feature of mature
DCs, including monocyte-derived and CD11c1 blood DCs.
The biological activities of MIP-3a and MIP-3b on
other immune cells have been poorly characterized thus
far. MIP-3a and MIP-3b have been shown to induce ar-
rest of lymphocytes rolling under flow conditions, MIP-3a
acting mainly on memory CD4 T cells and MIP-3b on
most lymphocytes (77). Furthermore, MIP-3a induces mi-
gration of T cells but is inactive on monocytes and neutro-
phils (reference 45 and our observations) and MIP-3b at-
tracts T and B lymphocytes but not granulocytes and
monocytes (78).
Regarding in vivo expression, MIP-3a mRNA is mainly
expressed in lung, appendix, liver, and some lymphoid or-
gans (47, 50–52) and by many cell types both of hemato-
poietic and nonhematopoietic (fibroblasts, keratinocytes,
endothelial cells) origins (47, 50–52, and our observations).
Moreover, the production of MIP-3a is induced by in-
flammatory stimuli such as LPS or TNF-a by endothelial
cells and monocytes (50, 52, and our observations). Now,
we show by in situ hybridization that MIP-3a is expressed
in tonsil by inflamed epithelium, a site known to be infil-
trated by immature DCs. In contrast, the expression of
MIP-3b mRNA is restricted to lymphoid organs and to
cells of hematopoietic origin, in particular DCs as well as B
lymphocytes and monocytes (49, 52, and our observations).
In tonsil, MIP-3b mRNA as detected by in situ hybridiza-
tion, is expressed by scattered cells within T cell–rich areas
where mature IDCs home.
Thus, it is tempting to speculate that upon local injury,
immature DCs or their precursors, expressing CCR6,
would be attracted to the site of inflammation through the
local production of chemokines like MIP-3a. Such accu-
mulation of DCs has been observed in the airway epithe-
lium of rat after intratracheal antigen instillation (3). After
antigen uptake, TNF-a– or LPS-induced maturation would
turn off MIP-3a responsiveness, thereby enabling emigrat-
ing DCs to escape the local gradient of MIP-3a. Simulta-
neous acquisition of CCR7 would drive maturing DCs
into the paracortical area of lymphoid organs in response to
the production of MIP-3b by cells spread over the T cell
zone. As MIP-3b can attract mature DCs and lymphocytes
(77, 78), it is likely to play a key role in helping antigen-
loaded DCs to meet specific T cells.
Figure 9. CD11c1 peripheral blood DCs respond to MIP-3b but not
to MIP-3a upon spontaneous maturation. CD11c1 DCs were FACSÒ
sorted from PBLs according to their lack of lineage markers and expres-
sion of CD4 and CD11c (see Materials and Methods). (A) The responses
to MIP-3a (500 ng/ml) and to MIP-3b (500 ng/ml) were determined af-
ter FACSÒ sorting and after 16-h culture with GM-CSF. Migration assays
were performed in Boyden microchambers. Results are expressed as
number of migrating cells per two low power fields (original magnifica-
tion: 320). Results are representative of four experiments. (B) The ex-
pression of CCR7 mRNA was assessed by semiquantitative RT-PCR.
Results at 35 cycles are shown, and PCR for b actin is shown at 21 cycles
as an internal mRNA control. Results are representative of three experi-
ments.
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Figure 10. In vivo MIP-3a is expressed in inflamed epithelium and MIP-3b within T cell–rich areas of tonsils. Human tonsil sections were hybridized
with antisense (A–D, F–I) and sense (E and J) 35S-labeled RNA probes for MIP-3a (A–E) and MIP-3b (F–J), and were exposed for 24 d. A and F, D and
E, and I and J are serial cryostat sections. D and I are higher magnification of inset areas of C and H, respectively. (B and G) Darkfield illuminations are
the same areas shown in A and H, respectively. MIP-3a mRNA is strongly expressed within epithelial crypts, no signal is seen within the T cell–rich ar-
eas nor the B cell–rich areas (A–C). MIP-3a mRNA is expressed in cells lining the epithelial crypts (D). MIP-3b mRNA is detected within the T cell–
rich areas, no signal is seen within the B cell follicles nor in the epithelial crypts (F–H). MIP-3b mRNA is strongly expressed in scattered cells spread over
the T cell areas around blood vessels (I). The sense probes do not generate background hybridization (E and J). Original magnification: A–C and F–H,
340; D and E, 3100; (I and J), 3200.
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